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Abstract 
Background: Continuous infusion of propofol has been used to achieve sedation in children. However, the relation‑
ship between the effect‑site concentration (Ce) of propofol and sedation scale has not been previously examined. The 
objective of this study was to investigate the relationship between the Ce of propofol and the University of Michigan 
Sedation Scale (UMSS) score in children with population pharmacodynamic modeling.
Methods: A total of 30 patients (aged 3 to 6 years) who underwent surgery under general anesthesia with propofol 
and remifentanil lasting more than 1 h were enrolled in this study. Sedation levels were evaluated using the UMSS 
score every 20 s by a 1 μg/mL stepwise increase in the Ce of propofol during the induction of anesthesia. The pharma‑
codynamic relationship between the Ce of propofol and UMSS score was analyzed by logistic regression with nonlin‑
ear mixed‑effect modeling.
Results: The estimated Ce50 (95% confidence interval) of propofol to yield UMSS scores equal to or greater than n 
were 1.84 (1.54–2.14), 2.64 (2.20–3.08), 3.98 (3.66–4.30), and 4.78 (4.53–5.03) μg/mL for n = 1, 2, 3, and 4, respectively. 
The slope steepness for the relationship of the Ce versus sedative response to propofol (95% confidence interval) was 
5.76 (4.00–7.52).
Conclusions: We quantified the pharmacodynamic relationship between the Ce of propofol and UMSS score, and 
this finding may be helpful to predict the sedation score at the target Ce of propofol in children.
Trial registration: http:// www. clini caltr ials. gov (No.: NCT03 195686, Date of registration: 22/06/2017).
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Background
Procedural sedation induces anxiolysis, unconsciousness, 
and analgesia for patient’s comfort. Pediatric patients 
often require sedation for examination, brief procedures, 
and imaging studies because of anxiety, fear, distress, 
and agitation owing to parental separation [1]. Propo-
fol is widely used for pediatric procedural sedation as 
it has a potent dose-dependent hypnotic action [2–6]. 
Additionally, propofol reduces airway reflex, postop-
erative nausea and vomiting, and emergence delirium in 
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pediatric patients and is necessary for children suscep-
tible to malignant hyperthermia [7, 8]. The important 
issues during propofol sedation are avoiding overdosage 
or underdosage [9, 10], and maintaining adequate spon-
taneous ventilation and vital signs [5, 11–13].
For longer procedural sedation, continuous infusion 
of propofol should be used [14, 15]. Several studies have 
investigated the manual infusion dosage required to 
achieve sedation in children [7, 14, 15]. However, as the 
central volume of distribution and clearance of propo-
fol changes during development, manual infusion of 
propofol need age-specific dosage adjustment [7, 8, 10, 
14–16]. Additionally, manual infusion of propofol guided 
by clinical assessment of the sedation scale is associated 
with an increased risk of overdosage or underdosage 
when compared to that with target-controlled infusion 
(TCI) [8–10]. Hypotension, bradycardia, apnea, airway 
obstruction, and delayed recovery are associated with 
overdosage of propofol [11, 17, 18] while insufficient 
concentrations of propofol can result in awakeness, sym-
pathetic stimulation, and unsatisfactory procedural con-
dition [10, 11].
TCI of propofol has been used in anesthesia for more 
than 20 years, and its use has spread widely because of 
the convenience in usage, stable blood concentration 
estimations, and rapid recovery it offers [10, 11, 19, 20]. 
The development of pediatric TCI models for propofol, 
such as those by Kataria et  al. [21], Absalom et  al. [22], 
and Choi et  al. [16] has led to the widespread usage of 
TCI of propofol for inducing sedation and general anes-
thesia in children [8, 10, 12, 16, 23–25].
Recently, studies have shown that TCI of propofol has 
a more stable bispectral index (BIS) within the target 
range with less dose adjustment than that of manual infu-
sion during general anesthesia in children [9, 10]. How-
ever, electroencephalography-derived monitors are not 
always feasible in various clinical settings (e.g., magnetic 
resonance imaging) of pediatric procedural sedation. 
Therefore, establishing the relationship between the Ce 
of propofol and sedation scale will be helpful for targeted 
procedural sedation in pediatric patients.
We hypothesized that an adequate pharmacodynamic 
model between Ce of propofol and University of Michi-
gan Sedation Scale (UMSS) can be made in children, and 
planned a prospective modeling study.
Methods
Patient recruitment and anesthetic methods
The study was approved by the Institutional Review 
Board of Seoul National University Hospital (Ref No; 
1705–110-855). Written informed consent was obtained 
from one of the parents or legal guardians for minor 
patients, and patients were given a verbal explanation 
and had the opportunity to ask questions about the study 
methods and purposes. Informed consent was obtained 
from each patient. All procedures followed the principles 
of the Declaration of Helsinki and its subsequent revi-
sions. This study was registered at http:// www. clini caltr 
ials. gov (NCT03195686, Principal investigator; Hee-Soo 
Kim, Date of registration; 22/06/2017) prior to patient 
enrollment.
A total of 30 patients (aged 3 to 6 years) who underwent 
surgery under general anesthesia lasting more than 1 h 
were enrolled in this study. The exclusion criteria were 
obstructive sleep apnea, expected difficult airway man-
agement, or any conditions affected by propofol, such as 
mitochondrial diseases.
All patients fasted according to the guidelines of the 
American Society of Anesthesiologists. Baseline heart 
rate (HR) and noninvasive blood pressure (BP) were 
measured on admission. An intravenous route was 
established before transferring the patient to the oper-
ating theater, and patients received intravenous mida-
zolam 0.1 mg/kg as premedication. Standard monitoring, 
including an electrocardiogram, HR, noninvasive BP at 
1-min intervals, peripheral oxygen saturation  (SpO2), 
and end-tidal carbon dioxide  (ETCO2), was performed 
after arrival in the operating theater. A facial mask was 
applied, and oxygen (6 L/min) was administered. Lido-
caine administration (0.5 mg/kg) was followed by propo-
fol infusion with the effect site TCI mode (Kim and 
Choi’s model [16]) set at a Ce of 1 μg/mL. The propo-
fol infusion line was connected just near the patient’s 
intravenous catheter site to minimize the dead space. 
After reaching the target, Ce was maintained for 2 min 
to ensure equilibration, and the target Ce was increased 
by 1 μg/mL for each step (up to Ce = 6 μg/mL). The Kim 
and Choi’s pediatric propofol model was recently devel-
oped and externally validated in previous studies [16, 
25]. Administration of propofol was conducted using an 
infusion control software (ASAN pump program, http:// 
fit4NM. org/d_ asanp ump, last accessed: 03 Nov, 2020) 
with a syringe pump (Pilot Anesthesia 2, Fresenius Kabi 
AG, Bad Homburg vdh, Germany). Detailed logs of infu-
sion, including time and rate of infusion, were automati-
cally recorded during the whole infusion period [26]. The 
criteria for determining the UMSS score are presented in 
Table 1.
UMSS was assessed by an experienced pediatric 
anesthesiologist (Y.E.J.) who was blinded to the Ce 
of the propofol. Response to a verbal conversation 
(UMSS = 1, sleepy appropriate response to sound) 
was assessed by calling the patient’s name. Light tac-
tile stimulation was applied (UMSS = 2, moderately 
sedated) by touching the patient’s eyebrows, and sig-
nificant physical stimulation was applied (UMSS = 3, 
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deeply sedated) by squeezing the trapezius. After the 
patient exhibited a UMSS = 4 (unarousable), rocuro-
nium 0.6 mg/kg was administered to facilitate tracheal 
intubation, and remifentanil was started for general 
anesthesia. During anesthesia, the target Ce values 
for propofol and remifentanil were controlled by the 
attending anesthesiologists. Ventilation was adjusted 
to a tidal volume of 7 mL/kg, and the respiratory rate 
was adjusted to maintain  ETCO2 of 35–40 mmHg; the 
inspired oxygen fraction was 0.4 in 2 L of fresh gas. 
Body temperature was continuously monitored and 
maintained above 35.5 °C with active warming.
On the closure of the surgical wound, propaceta-
mol 15 mg/kg was administered for postoperative 
pain control. Remifentanil administration was halted 
10 min before emergence and propofol administration 
was stopped by the attending anesthesiologist’s deci-
sion. In addition, HR, BP,  SpO2, and  ETCO2 were con-
tinuously monitored throughout the study period and 
anesthesia. When patients met the extubation criteria 
(UMSS = 0 or 1, train-of-four ratio > 0.9, and adequate 
tidal volume > 6 mL/kg), they were extubated and 
transferred to a post-anesthesia care unit (PACU). All 
adverse events (hypertension, BP increased more than 
20% of baseline values; hypotension, BP decreased 
more than 20% of baseline values; tachycardia, HR 
increased more than 20% of baseline values; bradycar-
dia, HR decreased more than 20% of baseline values; 
apnea, no spontaneous breathing for 15 s or desatura-
tion; and < 95% of  SpO2) were observed and recorded 
during the study period (from the induction of anes-
thesia to the discharge from PACU).
On completion of the study, the infusion history for 
propofol was obtained from the ASAN pump program. 
To eliminate the confounding effect of surgical pain 
and analgesic medications (remifentanil and propacet-
amol), only UMSS scores and the Ce values of propofol 
during induction of anesthesia were used for pharma-
codynamic modeling of propofol sedation. Statisti-
cal analyses for descriptive statistics were performed 
using SPSS 23.0 for Windows (IBM SPSS Statistical 
Software, Chicago, IL, USA).
Investigation of the relationship between  Ce of propofol 
and sedation scale; pharmacodynamic modeling
To transfer ordinal UMSS scores into binary outcomes, 
we defined the UMSS score being equal to or greater 
than a given level n as a “response” and otherwise as a 
“non-response,” which were converted to 1 and 0, respec-
tively. Logistic regression analysis was performed to 
examine the pharmacodynamic relationship between the 
Ce of propofol and UMSS scores. Referring to previous 
similar studies [27, 28], the probability of response to a 
given level of sedation score [P (UMSS) ≥ n] at a given 
Ce of propofol was analyzed using the following sigmoid 
Emax model:
where Ce50UMSS ≥ n is defined as a steady-state effect-site 
concentration of propofol with a 50% probability of a 
UMSS score equal to or greater than n, and γ is the Hill 
coefficient describing the slope steepness for the rela-
tionship of the Ce versus sedative response. The value 
of γ was assumed to be the same for all the sedation 
scores.
Based on the notion of “response” and “non-response” 
mentioned above, observation of a specific UMSS score 
n at a given Ce can be explained as the co-occurrence of 
a “response” for scores 0, 1, ..., n and a “non-response” for 
levels n + 1, …, 4. Therefore, the probability of observing 
the UMSS score of n at a given Ce can be calculated as 
the product of probabilities for “response” for levels 0, 1, 
…, n and “non-response” for levels n + 1, …, 4. Hence, P 
(UMSS = n) can be calculated as follows:
By this estimation, we defined the predicted 
UMSS score for a given Ce as the score with the 
highest probability and compared predicted and 
observed scores.















(1 − P(UMSS ≥ k))
(0 ≤ n ≤ 4).
Table 1 University of Michigan Sedation Scale
0 Awake and alert
1 Minimally sedated: tired/sleepy, appropriate response to verbal conversation and/or sound
2 Moderately sedated: somnolent/sleeping, easily aroused with light tactile stimulation or a 
simple verbal command
3 Deeply sedated: deep sleep, arousable only with significant physical stimulation
4 Unarousable
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Model building and evaluation
We set our primary outcome as Ce50UMSS  ≥  n and their 
relative standard errors obtained from the pharma-
codynamic model. Secondary outcomes were distri-
bution of UMSS scores against Ce of propofol, other 
derived parameters such as gamma, P  (UMSS ≥ n), or 
P  (UMSS = n) for each UMSS score from the model, 
demographic data, and incidence of adverse events such 
as desaturation, apnea, or hemodynamic instability. 
Among the data obtained during infusion of propofol, 
several points were selected, including the start of infu-
sion and increment of UMSS score to 1, 2, 3, and 4. In 
addition, to reflect the change in Ce and obtain sufficient 
sample points, one additional point for each UMSS score 
was taken, which was set as the midpoint of the period 
in which the specific UMSS score was maintained, except 
for the score of 4. For UMSS score of 4, data at the time 
point when 20 s were elapsed after the score was changed 
were extracted.
The pharmacodynamic model was built using the 
Laplace method of NONMEM® 7.4.4 (ICON Develop-
ment Solutions, Dublin, Ireland) via an interface pro-
gram named Pirana® 2.9.9 (http:// pirana- softw are. com, 
currently only provided by Certara, Princeton, NJ, USA). 
The NONMEM software calculated the likelihood (L) of 
the observed response on the UMSS score (R) as follows:
Inter-individual variability for each of Ce50UMSS ≥ n and 
gamma were estimated via a log-normal method or fixed 
to zero if necessary.
To evaluate model performance, we used the meth-
ods described by previous investigators to calculate the 
prediction probability (Pk) of the predicted UMSS score 
given the observed UMSS score. With a pharmacokinetic 
tool program named fit4NM 4.6.0 (Eun-Kyung Lee and 
Gyu-Jeong Noh; http:// www. fit4nm. org/ downl oad/ 246; 
last accessed: 03 Nov, 2020), Pk was calculated as follows 
[27–29]:
where Pk = 1 indicates the complete agreement between 
the observed level of sedation and calculated index; 
Pk = 0.5 is the random relationship between the two; and 
Pk = 0 indicates complete disagreement.
In addition, we used a non-parametric bootstrap 
method to perform an internal validation of the model 
using the Perl-speaks-NONMEM (PsN) software ver. 
4.9.0 (https:// uupha rmaco metri cs. github. io/ PsN/). Boot-
strapping was performed by resampling with the replace-
ment of individuals to create a new dataset with an equal 
number of individuals as that in the original dataset 
L = R× P (UMSS ≥ n)+ (1− R)× [1− P (UMSS ≥ n)]
Pk =
Somers′ d + 1
2
,
(n = 30). Dataset formation and parameter estimation 
were repeated 1000 times. The 2.5–97.5% percentiles of 
the distribution of the parameter estimates across the 
nonparametric bootstrap replicates were used to build a 
95% confidence interval and compared with the param-
eter estimates of the final model.
Comparison with other pediatric models
As Kim and Choi’s model is not of widespread use nor 
commercially available, we compared the estimated Ce 
values from Kim and Choi’s model and from other com-
mercially available models, which are the Kataria model 
[21] and the Schüttler’s model [30] used in the Paed-
fusor. As we have complete infusion history for each 
patient, we simulated the infusion and obtained esti-
mated plasma concentration and Ce of propofol for every 
time point using PKPD tools for excel by C. Minto and T. 
Schnider (http:// pkpdt ools. com/ excel/ downl oads/). We 
assumed actual use of the Kataria model and the Paed-
fusor model via commercially available Agilia® SP TIVA 
infusion pump (Software version 2.2, Fresenius Kabi, 
Fresenius Kabi AG, Bad Homburg vdh, Germany) and 
used pharmacokinetic-pharmacodynamic parameters 
based on literature [21, 31] and offered by the manufac-
turer. Afterward, we sorted estimated Ce values for time 
points included in the pharmacodynamic modeling and 
compared predictions from Kataria model or Paedfu-
sor model with predictions from Kim and Choi’s model 
via the Bland-Altman plot using MedCalc® (ver. 20.008, 
MedCalc Software Ltd., Ostend, Belgium).
Sample size calculation
Since this study was an exploratory study not intended 
to test a specific hypothesis, the calculation of the sam-
ple size was not necessary. We referred to a similar study 
on the pharmacodynamics of propofol study in terms of 
modified observer’s assessment of the alertness/sedation 
scale, in which data from 30 patients were used [32].
Results
A total of 32 patients were recruited, and 30 completed 
the study. Incomplete data collection resulted in the loss 
of two patients from the study. Demographic data are 
presented in Table 2.
The relationship between the Ce of propofol and cor-
responding UMSS scores is presented in Fig.  1. At a 
given UMSS score, the Ce of propofol varied between 
individuals.
All 237 pairs of Ce of propofol and UMSS score were 
used for the development of the model. The estimated 
population parameters of the Ce50 of propofol at a given 
UMSS score and gamma are presented in Table 3. When 
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the Ce of propofol increased, the depth of sedation was 
deeper and UMSS score was higher.
Figure 2 presents the probability of showing the degree 
of sedation corresponding to a given UMSS score or 
higher according to the Ce of propofol in children. In 
addition, the calculated probability for each specific 
UMSS score according to Ce of propofol is presented.
The predicted UMSS scores that had the highest prob-
ability according to changes in Ce are shown in Table 4.
The calculated Pk (95% CI) was 0.770 (0.731–0.809). 
This value implies an excellent degree of agreement 
between the observed and predicted UMSS scores and, 
therefore, acceptable performance of the model. In addi-
tion, the observed and predicted distributions of the 
UMSS score according to the range of Ce are shown in 
Fig. 3.
For comparison of commercially available models with 
the Kim and Choi’s model, data from 23 patients were 
used, since infusion logs for seven patients were flawed. 
Excluding points before the start of the infusion, total of 
166 time-points were included. Figure 4 shows the Bland-
Altman plot for differences in the estimated Ce of propo-
fol among different models. The Kim and Choi’s model 
predicted the Ce of propofol to be higher than the Kataria 
model and the Paedfusor model, with biases (95% CI) of 
24.2% (21.8–26.6%) and 27.9% (25.1–30.7%), respectively.
There were no complications such as respiratory 
depression after premedication with midazolam. Dur-
ing the induction of sedation, all patients were able to 
breathe spontaneously, and there were no desaturation 
events. At UMSS score = 4, five patients required jaw 
thrust to maintain airway patency with spontaneous 
breathing, but desaturation did not occur. No hyper-
tension, hypotension, bradycardia, or tachycardia was 
observed in any patient. All patients were transferred to 
the PACU without any desaturation events or other res-
piratory complications after extubation and had a UMSS 
score = 1. In the PACU, no patients experienced apnea or 
desaturation or had unstable blood pressure or heart rate.
Discussion
This study was the first to quantify the relationship 
between Ce of propofol and the sedation probabil-
ity in children according to the UMSS score using the 
pharmacodynamic model. The findings of this study 
may provide important information based on which 
anesthesiologists can estimate the sedation probability 
Table 2 Demographics and characteristics of the patients 
(n = 30)
Values are expressed as number or mean (standard deviation)
Clinical variables Values
Sex (M/F) 16/14
Age (years) 4.8 (0.95)
Height (cm) 109.6 (9.4)
Weight (kg) 19.2 (4.8)
Surgery
 Otolaryngeal surgery 19
 Orthopedic surgery 3
 Plastic surgery 2
 Urologic surgery 3
Fig. 1 UMSS score vs Ce of propofol. This figure shows a scattered plot of observation of the University of Michigan Sedation Scale (UMSS) score 
versus effect‑site concentration (Ce) of propofol
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in children as assessed by the UMSS at a given Ce of 
propofol.
Previous studies by McFarlan et al. [14] and Steur et al. 
[15] have suggested a manual propofol dosage scheme for 
total intravenous anesthesia in children aged 3–11 years 
and < 3 years, respectively. To produce a steady-state 
blood concentration of 3 μg/mL by manual infusion of 
propofol for children aged 3–11 years [14], a loading 
dose of 2.5 mg/kg was followed by continuous infusion 
of 15 mg/kg/hr for the first 15 min, 13 mg/kg/hr from 15 
to 30 min, 11 mg/kg/hr from 30 to 60 min, 10 mg/kg/hr 
from 1 to 2 h, and 9 mg/kg/hr from 2 to 4 h. For children 
aged < 3 years, Steur and colleagues proposed different 
propofol dosage schemes for each four age group [15] 
(0–3 months, 3–6 months, 6–12 months, and 1–3 years), 
and they reduced the continuous infusion rate every 
10 min to prevent delayed recovery.
This complexity of manual infusion is due to the phar-
macological properties of propofol in pediatric patients 
[14, 15]. Younger children require higher induction and 
maintenance doses because of a greater volume of dis-
tribution and elevated systemic clearance [16]. Addi-
tionally, lighter children require a higher weight-based 
infusion rate of propofol to maintain a certain level 
of Ce [14–16]. The context-sensitive half time in chil-
dren is significantly longer than that in adults, and it is 
increased by prolonged infusion [14]. Therefore, main-
taining an appropriate level of sedation with the man-
ual infusion of propofol is cumbersome and difficult in 
various clinical situations of pediatric sedation [10, 33].
TCI uses allometric scaling to describe age-related 
changes in the volume of distribution and metabolic 
clearance in pediatric patients of various ages [4, 16]. 
Changes in the pharmacological parameters are auto-
matically calculated in pharmacokinetic models for 
more accurate drug delivery and reduced variability [11]. 
TCI is typically associated with less respiratory depres-
sion, less dose of propofol, and faster recovery [11]. In 
pediatric patients, TCI of propofol shows less variability 
in the BIS with less dose adjustment compared with that 
of manual infusion during general anesthesia [9, 10]. 
Therefore, TCI gives a more stable sedation than man-
ual infusion does in pediatric patients.
A previous study investigated the population phar-
macodynamics of midazolam and sedation score in 
adult patients after coronary artery bypass grafting 
[28]. The basic idea of the present study was adapted 
from this previous study. The clinical observational 
findings of our study were similar to those of this study. 
Although the drugs investigated in the studies (mida-
zolam versus propofol) are different, the range of drug 
concentrations at a given sedation score varied, which 
is commonly observed during sedation (Fig. 1). There-
fore, it would be reasonable to expect the probability of 
a certain sedation score at a given drug concentration.
In our final model, inter-individual variability for Ce50 
and gamma was fixed to zero. When we assumed inter-
individual variability during the modeling, significant 
shrinkage, which was greater than 30%, occurred for all 
of the parameters except for the Ce50UMSS ≥  2, while not 
substantially reducing the objective function value. As 
a high level of shrinkage is indicative of a high level of 
estimation error [34], we decided not to assume inter-
individual variability. Therefore, we used a naïve pooled 
data approach that assumes inter-individual variability as 
zero, and accordingly, within subject correlation was not 
assumed. A similar method has been used in previous 
studies [27, 32]. The bootstrap results showed fair agree-
ment with the original estimates from the final model.
We did not present classical tools for model perfor-
mance such as the goodness-of-fit plot or visual predic-
tive check in this study. Such methods were difficult to 
apply in this model because the observed UMSS scores 
were ordinal variables rather than continuous variables 
and were expressed as integers, whereas the predicted 
values were completely different probability values. 
Although we presented the distribution of predicted 
UMSS scores in Fig. 3, it was only intended to provide an 
interpretation to aid the application of our model in clini-
cal settings.
In pediatric patients, Munoz et al. investigated the Ce of 
propofol required to produce hypnosis in children aged 
3–11 years using BIS monitoring [35]. In that study, the 
mean ECe50 for hypnosis assessed at BIS value = 50 was 
3.65 μg/mL. Additionally, a retrograde study of propofol 
sedation with the Paedfuor plasma TCI model in children 
aged < 7 years reported that the target Ce of propofol for 
long-duration of immobilization and spontaneous ven-
tilation was 4.3 μg/mL during proton radiation therapy 
Table 3 Parameter estimates of the population pharmacodynamics 
model for Ce of propofol and UMSS score (n = 30)
Parameter estimates were obtained via the Laplace method using NONMEM® 
7.4.4 (ICON Development Solutions, Dublin, Ireland). Inter-individual random 
variability was not assumed. Bootstrap analysis was repeated 1000 times. 
Ce Effect-site concentration, UMSS University of Michigan Sedation Scale, 
Ce50UMSS ≥ n Effect-site concentration of propofol with 50% probability of UMSS 
score equal to or greater than n, RSE Relative standard error
Parameter Estimate, (RSE, %), [95% CI]
(μg/mL)
Median (2.5–97.5%) of 
bootstrap replicates (μg/
mL)
Ce50UMSS ≥ 1 1.84 (8.3) [1.54–2.14] 1.85 (1.67–2.04)
Ce50UMSS ≥ 2 2.64 (8.6) [2.20–3.08] 2.66 (2.40–2.97)
Ce50UMSS ≥ 3 3.98 (4.1) [3.66–4.30] 4.00 (3.79–4.19)
Ce50UMSS ≥ 4 4.78 (2.7) [4.53–5.03] 4.81 (4.64–4.96)
γ 5.76 (15.6) [4.00–7.52] 5.78 (4.89–7.32)
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[12]. These values matched the 3.98 [3.66–4.30] μg/mL 
of Ce50, which corresponded to a UMSS = 3, in our study. 
From the results of these two studies, we inferred that 
a UMSS = 3 may correspond to a BIS value of 50 and 
can produce deep sedation for long-duration radiologic 
procedures.
Based on the present study (Table  2), we suggest an 
initial target Ce of 1.5–2.0 μg/mL for minimal sedation 
(UMSS = 1), 2.0–3.0 μg/mL for moderate sedation with 
light tactile stimuli (UMSS = 2), and 3.5–4.0 μg/mL for 
deep sedation with significant physical stimuli or require 
immobilization (UMSS = 3). The Ce of propofol should be 
adjusted for specific procedure-related stimulation, such 
as noise, tactile stimuli, and pain because the depth of 
sedation and degree of respiratory depression can change 
accordingly. Because the depth of sedation by the UMSS 
score changes rapidly in the Ce range of 2.0–4.0 μg/mL, 
and the change cannot be predicted 100% accurately, we 
Fig. 2 Estimation of probabilities of UMSS score. 2A depicts the estimation of the probability that the University of Michigan Sedation Scale (UMSS) 
score is n or more (n = 1, 2, 3, 4) according to the effect‑site concentration (Ce) of propofol. Probabilities were calculated for Ce50UMSS ≥ n with a 
pharmacodynamic model using the Laplace method. 2B shows the probability for each specific UMSS score according to Ce of propofol. Detailed 
calculation methods are presented in the methods section. The probabilities for UMSS scores = 1, 2, and 3 show a single peak, and the probability 
of UMSS score = 4 shows a gradual increase as the Ce of propofol increases. Ce50UMSS ≥ n, the steady‑state effect‑site concentration of propofol with a 
50% probability of UMSS score being equal to or greater than n 
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suggest that the concentration should be more precisely 
controlled with a smaller incremental dose and close 
observation of the patient. Consequently, monitoring the 
depth of sedation using electroencephalography-based 
devices would be helpful for propofol-induced sedation 
in pediatric patients [9].
On comparison of the Kim and Choi’s model with com-
mercially available Kataria model and Paedfusor model, 
the Kim and Choi’s model predicts the Ce to be about 24 
to 28% higher than other models. Considering that bias 
within 30% is usually regarded acceptable when evaluat-
ing performance of pharmacokinetic-pharmacodynamic 
models, we can say that our model for UMSS score can 
be applied to other popular models such as the Kataria 
model and the Paedfusor model. Still, we want to recom-
mend using slightly lower target Ce values when using 
models on the market, along with continuous feedback 
from patients’ observed state of sedation.
This study has several limitations. First, the relationship 
between the Ce of propofol and UMSS score was evalu-
ated during general anesthesia, not during procedural 
sedation. To eliminate various confounding effects, this 
model used data only during anesthesia induction. As TCI 
ensures a certain Ce of propofol, the UMSS score did not 
change during a constant target Ce of propofol. Therefore, 
Table 4 Predicted UMSS scores according to change in the Ce of 
propofol via Kim and Choi’s model
Predicted UMSS scores were determined as the score with the highest 
probability at the given Ce
UMSS University of Michigan Sedation Scale, Ce Effect-site concentration
UMSS score Ce (μg/mL)
0 Ce < 1.9
1 1.9 ≤ Ce < 2.7
2 2.7 ≤ Ce < 4.0
3 4.0 ≤ Ce < 4.8
4 Ce ≥ 4.8
Fig. 3 Observed vs predicted distribution of UMSS. The proportions of each observed and predicted University of Michigan Sedation Scale (UMSS) 
score according to the range of the effect‑site concentration (Ce) of propofol are shown. 3A is for observed and 3B is for predicted UMSS score. The 
predicted UMSS score was determined as the score with the highest probability for a given Ce of propofol. Each section of Ce is set such that the 
values rounded from the first decimal place are included in the same section
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although this study lacks data from during the mainte-
nance of sedation, the pharmacodynamic model can pro-
vide meaningful information for pediatric sedation using 
propofol TCI. Second, the depth of anesthesia was not 
measured with electroencephalography-based monitors in 
this study. Additionally, the depth of sedation after reach-
ing the UMSS = 4 could not be assessed. To minimize 
the bias in estimating the Ce50 of propofol at UMSS = 4, 
we used the Ce of propofol when the patient reached the 
UMSS = 4 and 20 s after the subject reached the UMSS = 4. 
Third, the plasma concentration of propofol was not meas-
ured in this study. As minimal premedication was given 
to the patients of this study, serial blood sampling was 
not possible. Kim and Choi’s pediatric propofol model, 
which was used in this study, was externally validated and 
showed good performance in achieving the target propofol 
plasma concentration in children aged < 12 years [16, 25]. 
Also, as mentioned above, prediction of Ce values with the 
Kim and Choi’s model is acceptable when regarding pre-
dictions from previous pediatric models as gold standard. 
Finally, premedication with intravenous midazolam could 
affect the sedation score given the Ce of propofol. How-
ever, 0.1 mg/kg of midazolam was not sufficient to cause 
a significant sedative effect, and as premedication with 
midazolam has been widely performed in general anesthe-
sia and procedural sedation in children [36], it would not 
be different from clinical practice.
Conclusions
In conclusion, the relationship between Ce of propofol 
and UMSS score with probability by the population phar-
macodynamic approach in children was established. This 
finding may be helpful in predicting the depth of sedation 
when using TCI of propofol in various pediatric proce-
dural sedation settings.
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